NCT06621316View on ClinicalTrials.gov

A Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese Subjects

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

May 30, 2025

Study Completion Date

June 30, 2025

Conditions
Overweight or Obesity
Interventions
DRUG

HRS-7535 Tablet

at multiple dose levels

DRUG

Placebo

at multiple dose levels (matching active arm HRS-7535 Tablet)

Trial Locations (1)

010000

Peking University Peoples Hospital, Beijing

All Listed Sponsors
lead

Shandong Suncadia Medicine Co., Ltd.

INDUSTRY

NCT06621316 - A Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese Subjects | Biotech Hunter | Biotech Hunter